This episode is part of Financial Forensics Labs — two shows, one forensic methodology: The Due Diligence Files traces how institutions collapse, The Signal Files traces how the good calls get made. Built from primary-record research by a 15-year capital markets professional.
Get to know the framework, the other show, and the tools built from it — all in one place.
Explore
Financial Forensics Labs — Forensic Finance Intelligence
Mallinckrodt's opioid trust was owed $1.6 billion. It closed out that entire obligation with one final $250 million payment — four days before the company filed for bankruptcy a second time. This is the GP/LP breakdown of how a confirmed Chapter 11 plan is not a permanent settlement, and what that means for pricing a mass tort trust's recovery waterfall.
The mechanism: Mallinckrodt's first bankruptcy was pre-arranged — a $1.6 billion opioid settlement negotiated with 47 state attorneys general in February 2020, eight months before the October Chapter 11 filing, with a restructuring support agreement already signed. The plan confirmed in March 2022 channeled opioid claims into a hub-and-spoke trust structure, paid partly in cash and partly in contingent value rights — equity-linked instruments whose value depended entirely on the company's future stock performance. That structural choice is the center of this episode: the trust wasn't just owed a payment schedule, it was holding paper whose worth depended on continued goodwill from a company it had no operational control over.
By June 2023, Mallinckrodt disclosed it would miss a scheduled $200 million payment. A group of hedge funds — including Silver Point Capital — had by then accumulated the company's post-emergence debt and equity and began negotiating a second Chapter 11 filing that would cut the remaining $1.275 billion claim down to a single $250 million payment and cancel the contingent value rights entirely. The court approved it in October 2023, calling it a reasonable exercise of business judgment — the same low bar that governs nearly every distressed restructuring decision.
The three-signal framework covers instrument type (cash vs. equity-linked settlement paper), creditor composition drift (distressed funds accumulating position in a company with unresolved mass tort liability), and how a missed trust payment should be treated as a covenant-breach-level red flag rather than an administrative delay. The active due diligence section adds a fourth check: whether a post-emergence trust has independent counsel with real standing to object to a subsequent filing, or shares infrastructure with the process that already produced one debtor-favorable outcome.
Closes with the aftermath — hedge funds emerging with equity in a ~$3 billion reorganized company, victims receiving $400–700 after fees, and the 2025 Mallinckrodt-Endo merger built partly on debt that used to be trust money.
Every collapse has a pattern. We dissect it. Layer by layer.
Mallinckrodt GP LP analysis, mass tort recovery waterfall, Chapter 11 institutional due diligence, contingent value rights risk, distressed debt creditor composition, opioid trust structuring, private credit mass tort exposure, second bankruptcy risk framework, business judgment standard bankruptcy, restructuring support agreement analysis, Silver Point Capital Mallinckrodt, hedge fund bankruptcy control, post-emergence creditor monitoring, opioid claimant trust structure, hub and spoke trust bankruptcy, institutional credit due diligence, distressed fund accumulation signal, bankruptcy covenant breach analysis, mass tort settlement durability, allocator due diligence framework, forensic accounting GP LP, Chapter 11 recovery pricing, corporate liability engineering, opioid manufacturer credit risk, Financial Forensics Labs, financial autopsy institutional, capital structure mass tort, bankruptcy fraud hexagon rationalization, credit investor red flags opioid, legacy liability due diligence
